Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.

Main Header
Go to Research

Featured Publication

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.

Published June 20, 2022
See all Publications

Aaron Hata, MD PhD, Principal Investigator

Mission

Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.

We are a diverse group of physicians & scientists with expertise in cell biology, pharmacology, genetics, immunology and computational biology.

Meet the Team

News — June 22, 2022

Return of the CCR Retreat!

The CCR Retreat is back! Hata Lab research was well represented by posters from Samar, Jamie, Hideko, Chendi and Justine.

Go to News

News — June 20, 2022

Lorlatinib analogs manuscript is published!

Aya, Jess and Satoshi's manuscript "Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer" is now published in Nature Cancer! This collaboration…

Go to News

We are looking for people to partner with us in our mission to improve treatments for patients with lung cancer.

Join Us Support Us

Supporters

We are privileged to partner with a number of individuals and organizations who support our research. We are grateful for their dedication to helping us in the fight against lung cancer.